Hepatitis D News and Research

RSS

Hepatitis D is a viral infection that causes liver inflammation (swelling of the tissue which occurs due to injury or infection) and damage.

Exploring the global health challenge of hepatitis D

Review explores the global impact of the hepatitis D virus (HDV) on public health, detailing its transmission, clinical course, diagnosis, and treatment options.

2 Jan 2024

Real-world studies show efficacy, safety of BLV monotherapy in patients with HDV-related compensated cirrhosis

In 2020, bulevirtide (BLV) was conditionally approved for treating chronic hepatitis delta (CHD), an inflammation of the liver caused by hepatitis D virus (HDV).

20 Mar 2023

New immunological treatment against hepatitis B and D viruses shows promising results in animal models

A new immunological treatment against hepatitis B and D viruses, both of which can cause liver cancer, shows promising results in animal models.

26 Aug 2022

World Hepatitis Day 2022: Why Accelerating the Fight Against Hepatitis Cannot Wait

In our latest interview, News-Medical speaks to Simon Parker, an infectious disease specialist, about hepatitis C diagnostics and testing, as well as why the global fight against hepatitis cannot wait.

28 Jul 2022

New combination therapy proven to be highly effective in HBV infection model

Around 260 million people, more than three percent of the global population, are chronically infected with the hepatitis B virus (HBV); in the long term, this often leads to complications such as liver cirrhosis and liver cancer.

4 Feb 2021

Oxysterol derivatives show powerful antiviral activity against SARS-CoV-2 in vitro

A new study describes the antiviral activity of oxysterols, or oxidized cholesterol derivatives, against SARS-CoV-2. These occur in nature, and are not only involved in lipid signaling pathways that modulate a host of processes within the body, including the immune response and lipid homeostasis.

3 Feb 2021

European Commission approves first drug for hepatitis D

What started off as basic research 25 years ago has now lead to a successfully approved drug: The entry blocker bulevirtide (brand name Hepcludex, formerly known as Myrcludex B), jointly developed by researchers from Heidelberg University Hospital (UKHD) and the Medical Faculty of Heidelberg, the DZIF and other partners, has now been approved by the European Commission.

5 Aug 2020

Benefits of routine childhood immunizations far outweigh the risk of SARS-CoV-2 transmission

The health benefits of maintaining routine childhood vaccination programmes in Africa during the COVID-19 pandemic far outweigh the risk of SARS-CoV-2 transmission that might be associated with clinic visits, according to a modelling study published in The Lancet Global Health journal.

19 Jul 2020

Study reveals antiviral effects of curcumin

Curcumin, a natural compound found in the spice turmeric, could help eliminate certain viruses, research has found.

17 Jul 2020

Experts develop a simple questionnaire to raise awareness about managing liver disease

Alcohol's popularity and its central place in socializing in Australia obscures the dangers of excessive drinking and possible liver disease, Flinders University experts warn.

11 Jul 2020

Remdesivir potently inhibits SARS-CoV-2 in human lung cell cultures

The news about remdesivir, the investigational anti-viral drug that has shown early promise in the fight against COVID-19, keeps getting better.

9 Jul 2020

Pasteurization of breast milk inactivates novel coronavirus

Pasteurizing breast milk using a common technique inactivates severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) making it safe for use, according to new research in CMAJ.

9 Jul 2020

Researchers map RNA structure throughout SARS-CoV-2 genome

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which is currently at the heart of a pandemic that has cost the world more than 550,000 lives, 12 million infections, and uncounted years of productivity, is an RNA virus with the largest genome among all such viruses. This 30 kb size virus has caused many difficulties for scientists in search of a vaccine.

9 Jul 2020

HCV testing and treatment at federally qualified health centers can be cost-fffective

New research from Boston Medical Center shows that routine Hepatitis C (HCV) testing at federally qualified health centers improves diagnosis rates and health outcomes for people with HCV infections in the United States, and is cost-effective.

8 Jul 2020

Analysis: How a COVID-19 vaccine could cost Americans dearly

Yes, of course, Americans' health is priceless, and reining in a deadly virus that has trashed the economy would be invaluable.

8 Jul 2020

Cerebrospinal fluid autoantibodies target the brain in some COVID-19 patients

A study conducted by German researchers has shown that the neurological symptoms observed in some patients with coronavirus disease 2019 (COVID-19) may be caused by autoantibodies targeting the brain.

7 Jul 2020

Scientists identify compounds that block replication of COVID-19 virus

As the death toll from the COVID-19 pandemic mounts, scientists worldwide continue their push to develop effective treatments and a vaccine for the highly contagious respiratory virus.

7 Jul 2020

SARS-CoV-2 detected in Santiago, Chile wastewater with very little loss of viral RNA

A preliminary report from Chile describes the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in sewage as a sensitive method to assess the circulation of viruses within a community.

7 Jul 2020

2021 health plans granted leeway to limit consumers’ benefit from drug coupons

Without medication to manage her plaque psoriasis, Jennifer Brown's face, scalp, trunk and neck periodically become covered in painful red, flaky patches so dry they crack and bleed.

6 Jul 2020

Thermo Scientific MAS Omni Infectious Controls launched to assess the performance of serological assays

Thermo Fisher Scientific, the world leader in serving science, today announced the availability of the Thermo Scientific MAS Omni Infectious Disease quality control sets for monitoring serological assays for analytes such as HIV 1&2, Hepatitis B & C virus, Syphilis and HTLV I/II.

From Thermo Fisher Scientific Inc. 3 Jul 2020

Hepatitis D News and Research

Further Reading

Exploring the global health challenge of hepatitis D

Real-world studies show efficacy, safety of BLV monotherapy in patients with HDV-related compensated cirrhosis

New immunological treatment against hepatitis B and D viruses shows promising results in animal models

World Hepatitis Day 2022: Why Accelerating the Fight Against Hepatitis Cannot Wait

New combination therapy proven to be highly effective in HBV infection model

Oxysterol derivatives show powerful antiviral activity against SARS-CoV-2 in vitro

European Commission approves first drug for hepatitis D

Benefits of routine childhood immunizations far outweigh the risk of SARS-CoV-2 transmission

Study reveals antiviral effects of curcumin

Experts develop a simple questionnaire to raise awareness about managing liver disease

Remdesivir potently inhibits SARS-CoV-2 in human lung cell cultures

Pasteurization of breast milk inactivates novel coronavirus

Researchers map RNA structure throughout SARS-CoV-2 genome

HCV testing and treatment at federally qualified health centers can be cost-fffective

Analysis: How a COVID-19 vaccine could cost Americans dearly

Cerebrospinal fluid autoantibodies target the brain in some COVID-19 patients

Scientists identify compounds that block replication of COVID-19 virus

SARS-CoV-2 detected in Santiago, Chile wastewater with very little loss of viral RNA

2021 health plans granted leeway to limit consumers’ benefit from drug coupons

Thermo Scientific MAS Omni Infectious Controls launched to assess the performance of serological assays

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News